Status:
NOT_YET_RECRUITING
REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Coronary Heart Disease (CHD)
Eligibility:
All Genders
18-75 years
Brief Summary
Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering ...
Eligibility Criteria
Inclusion
- Diagnosed with CAD and PCI was successfully performed.
- Presence of non-target lesions near the target lesion (more than 5mm proximal or distal), with stenosis of 20% to 50% and identifiable anatomical markers (e.g., branches, calcifications, stent edges).
- 18 to 75 years old.
- Written informed consent.
Exclusion
- Known autoimmune diseases, or taking immunosuppressive drugs for a long time before onset.
- Known familial hypercholesterolemia.
- Critical conditions (e.g., cardiogenic shock, acute heart failure).
- Severe renal insufficiency (eGFR \< 30 mL /(min·1.73m2)), or severe hepatic insufficiency (ALT or AST≥3 times the upper limit of normal).
- Severe underlying diseases (such as end-stage malignancies), life expectancy \< 1 year.
- Allergic to lipid-lowering medications.
- Pregnant, or trying to become pregnant, and breastfeeding women.
- Other conditions deemed unsuitable for inclusion by the researcher.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT06936111
Start Date
July 1 2025
End Date
July 1 2027
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Zhongshan Hospital
Shanghai, China